Mice tumor free and protected from metastases after treatment
The shells of a common plant virus, inhaled into a lung tumor or injected into ovarian, colon or breast tumors, not only triggered the immune system in mice to wipe out the tumors, but provided systemic protection against metastases, researchers from Case Western Reserve University and Dartmouth University report.
The scientists tested a 100-year-old idea called in-situ vaccination. The idea is to put something inside a tumor and disrupt the environment that suppresses the immune system, thus allowing the natural defense system to attack the malignancy.
That something–the hard coating of cowpea mosaic virus–caused no detectible side effects, which are a common problem with traditional therapies and some immunotherapies.
The team’s research is published in the journal Nature Nanotechnology.
“The cowpea virus-based nanoparticles act like a switch that turns on the immune system to recognize and fight against the tumor – as well as to remember it,” said Nicole Steinmetz, an assistant professor of biomedical engineering at Case Western Reserve, appointed by the Case Western Reserve School of Medicine.
“The particles are shockingly potent,” said Steven Fiering, professor of microbiology and immunology at Dartmouth’s Geisel School of Medicine. “They’re easy to make and don’t need to carry antigens, drugs or other immunostimmulatory agents on their surface or inside.”
The professors studied the nanoparticles with Dartmouth’s Pat Lizotte, a molecular and cellular biology PhD student; Mee Rie Sheen, a postdoctoral fellow; and Pakdee Rojanasopondist, an undergraduate student; and Case Western Reserve’s Amy Wen, a biomedical engineering PhD student.
Taking another shot
The immune system’s ability to detect and destroy abnormal cells is thought to prevent many cancers, according to the National Cancer Institute. But when tumors start to develop, they can shut down the system, allowing tumors to grow and spread.
To restart immune defenses, the scientists used the tumor itself as if it were the antigen in a vaccine–that is, the target for antibodies produced by the immune system.
The cowpea virus shell, with its infectious components removed, acts as the adjuvant–a substance that triggers and may enhance or prolong antigen-specific immune responses.
The process and results
The researchers first switched on the immune system in mice to attack B16F10 lung melanoma or skin melanoma, leaving the mice tumor-free. When the treated mice were later injected with B16F10 skin melanoma (to re-challenge the cured mice), four out of five mice were soon cancer free and one had a slow-growing tumor.
The nanoparticles proved effective against ovarian, breast and colon tumor models. Most of the tumors deteriorated from the center and collapsed. The systemic response prevented or attacked metastatic disease, which is the deadliest form of cancer.
“You get benefits against disease you don’t even know is there yet,” Fiering said.
“Because everything we do is local, the side effects are limited,” despite the strength and extent of the immune response, Fiering said. No toxicity was found.
Harsh side effects, such as fatigue, pain, flu-like symptoms and more are common with chemo and radiation therapies and with some immunostimulation drugs.
The researchers are now trying to understand how the virus shell stimulates the immune system.
“It’s not cytotoxic, there’s no RNA involved or lipopolysaccharides that may be used as adjuvants, and it’s not simply an irritant,” Steinmetz said. “We see a specific immune response.”
The Latest on: Immune response against cancer
[google_news title=”” keyword=”immune response against cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on:Iimmune response against cancer
- Breast cancer: An aggressive variant triggers a hunt for cureson December 9, 2022 at 10:21 am
Triple negative breast cancer is a hard-to-treat form that accounts for 15% of all cases, with recovery hopes emerging from chemotherapy drugs that stimulate the immune system and others that cause ...
- Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccineon December 8, 2022 at 5:44 am
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the maximum tolerated dose (MTD) has been ...
- Neoantigen Cancer Vaccine report provides a six-year forecast assessed on the basis of how the market is predicted to grow.on December 7, 2022 at 11:39 am
An in-depth analysis of the " Neoantigen Cancer Vaccine Market " for the time frame of 2022 to 2028 is provided in the study. Also provided are in-depth statistics, additional information, and ...
- Breaking down the shield preventing drugs and immune cells from entering intractable cancerson December 6, 2022 at 7:46 am
A group lead by Prof. Horacio Cabral (Visiting Scientist of iCONM/Associate Professor of Bioengineering, Graduate School of Engineering, University of Tokyo) has discovered a new approach for the ...
- HIV Vaccine: Study Shows It May Induce Key Immune Response in Early Studyon December 6, 2022 at 6:53 am
A Phase 1 study of a new experimental HIV vaccine is showing promising results among a small group of volunteers. The findings are showing that when a two-dose regimen of the vaccine is administered ...
- Whole body scan shows the complexity of the immunotherapy responseon December 5, 2022 at 8:00 am
Immune checkpoint inhibitors activate the body's immune system against tumors. Although this cancer treatment has shown remarkable success, the patient's chance of responding to the treatment remains ...
- Can mRNA vaccines cure cancer?on December 3, 2022 at 5:04 am
RNA technology transforms the human body into a virus-zapping vaccine factory, teaching cells how to make a protein that triggers an immune response against viruses ...
- Researchers develop a safer carrier for cancer vaccineson December 2, 2022 at 7:24 am
Lipid nanoparticle (LNP)-based messenger ribonucleic acid (mRNA) vaccines have recently emerged as a promising strategy for the prevention and treatment of cancers, as well as infectious diseases.
- HIV vaccine candidate induces immune response in early clinical trial: ‘An important step forward’on December 2, 2022 at 4:45 am
An experimental HIV vaccine has been found to induce broadly neutralizing antibody precursors among a small group of volunteers in a Phase 1 study. The findings suggest that a two-dose regimen of the ...
- Promising prostate cancer drug hints at improved immunotherapyon November 28, 2022 at 7:17 pm
Immunotherapy is a promising cancer treatment, but getting it to work against solid tumors is proving difficult. A new study has not only identified a drug that’s effective against solid tumors, but ...
via Bing News